XOMA Royalty (XOMA) Non-Current Debt (2010 - 2026)
XOMA Royalty (XOMA) reported Non-Current Debt of $88.8 million for Q1 2026, down 11.12% on a YoY basis from $99.9 million in Q1 2025, and down 7.91% sequentially from $96.5 million in Q4 2025.
XOMA Royalty (XOMA) Non-Current Debt (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 16 years of Non-Current Debt data on file, last reported at $88.8 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Debt fell 11.12% year-over-year to $88.8 million; the trailing twelve-month figure through Mar 2026 stood at $88.8 million (down 11.12% YoY), and the FY2025 full-year result was $96.5 million, down 9.75% from the prior year.
- Non-Current Debt declined to $88.8 million in Q1 2026, from $96.5 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $118.5 million in Q4 2023 to a low of $88.8 million in Q1 2026.
- A 4-year average of $105.6 million and a median of $106.9 million in 2024 frame the typical range for Non-Current Debt.
- Peak annual rise in Non-Current Debt reached 9.75% in 2025, while the deepest fall reached 12.74% in 2025.
- Tracing XOMA's Non-Current Debt over 4 years: stood at $118.5 million in 2023, then declined by 9.82% to $106.9 million in 2024, then decreased by 9.75% to $96.5 million in 2025, then declined by 7.91% to $88.8 million in 2026.
- Business Quant data shows XOMA's Non-Current Debt at $88.8 million in Q1 2026, $96.5 million in Q4 2025, and $102.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 88.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.83 Mn |
| Dec 31, 2025 | 96.45 Mn |
| Jun 30, 2025 | 102.20 Mn |
| Mar 31, 2025 | 99.93 Mn |
| Dec 31, 2024 | 106.88 Mn |
| Sep 30, 2024 | 108.09 Mn |
| Jun 30, 2024 | 115.08 Mn |
| Mar 31, 2024 | 114.53 Mn |
| Dec 31, 2023 | 118.52 Mn |
| Mar 31, 2021 | 11.65 Mn |
| Dec 31, 2020 | 12.76 Mn |
| Sep 30, 2020 | 20.99 Mn |
| Jun 30, 2020 | 23.50 Mn |
| Mar 31, 2020 | 25.14 Mn |
| Dec 31, 2019 | 27.09 Mn |
| Sep 30, 2019 | 28.70 Mn |
| Jun 30, 2019 | 23.35 Mn |
| Mar 31, 2019 | 20.85 Mn |
| Dec 31, 2018 | 21.69 Mn |
| Sep 30, 2018 | 22.03 Mn |